Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

112.91B

Market cap112.91B

Price-Earnings ratio

15.52

Price-Earnings ratio15.52

Dividend yield

4.52%

Dividend yield4.52%

Average volume

10.59M

Average volume10.59M

High today

—

High today—

Low today

—

Low today—

Open price

$55.80

Open price$55.80

Volume

0.00

Volume0.00

52 Week high

$62.89

52 Week high$62.89

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

With a market cap of 112.91B, Bristol-Myers Squibb(BMY) trades at $55.40. The stock has a price-to-earnings ratio of 15.52 and currently yields dividends of 4.52%.

Bristol-Myers Squibb(BMY) stock opened on 2026-06-18 at $55.80. The price climbed to — and dipped to —.

The Bristol-Myers Squibb(BMY)'s current trading volume is 0, compared to an average daily volume of 10.59M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

BMY News

Simply Wall St 11h

Bristol Myers Squibb Reports Strong Myeloma Trial Results And Early CAR T Progress

Bristol Myers Squibb (NYSE:BMY) reported positive late-stage clinical trial results for two multiple myeloma candidates. The company announced successful Phase...

TipRanks 2d

Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks...

Investor's Business Daily 2d

Biotech Whips Violently Between Red And Green — What's Going On? - Investor's Business Daily

...

Analyst ratings

61%

of 31 ratings

Buy

35.5%

Hold

61.3%

Sell

3.2%

More BMY News

Simply Wall St 2d

Bristol Myers Squibb Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion

Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, ad...

TipRanks 6d

Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a new early-stage trial to test how its...

TipRanks 6d

Bristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb has completed a real-world study titled “Patient C...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.